203506-39-2 Usage
Uses
Used in Scientific Research:
4-Bromo-2,8-Dimethylquinoline is utilized as a synthetic intermediate for the production of more complex chemical compounds. Its unique structure and reactivity make it a valuable component in the synthesis of various molecules, contributing to the advancement of chemical research and development.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 4-Bromo-2,8-Dimethylquinoline is employed as a building block for the synthesis of potential drug candidates. Its presence in the molecular structure can influence the pharmacological properties, such as solubility, stability, and bioavailability, which are crucial for the effectiveness and safety of the final drug product.
Used in Chemical Synthesis:
4-Bromo-2,8-Dimethylquinoline is used as a key intermediate in the synthesis of various organic compounds, including dyes, pigments, and other specialty chemicals. Its versatility in chemical reactions allows for the creation of a wide range of products with diverse applications across different industries.
Check Digit Verification of cas no
The CAS Registry Mumber 203506-39-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,3,5,0 and 6 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 203506-39:
(8*2)+(7*0)+(6*3)+(5*5)+(4*0)+(3*6)+(2*3)+(1*9)=92
92 % 10 = 2
So 203506-39-2 is a valid CAS Registry Number.
InChI:InChI=1/C11H10BrN/c1-7-4-3-5-9-10(12)6-8(2)13-11(7)9/h3-6H,1-2H3
203506-39-2Relevant articles and documents
4-Quinolinemethanol derivatives as purine receptor antagonists (1)
-
, (2008/06/13)
Use a compound of formula (I) wherein: R1is hydrogen or alkyl; R2and R3are independently selected from hydrogen, alkyl, aryl and heterocyclyle or together may form a ring or R1and R2or R3together may form an oxygen-containing, optionally fused ring pharmaceutically acceptable salts or prodrugs thereof, with the proviso that where R1and R4to R9are hydrogen, R2or R3is not 3-methoxy-4-benzyloxyphenyl or 2-dimethylaminoethoxymethyl, in the manufacture of a medicament for the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly A2Areceptors, may be beneficial. Said disorders are neurodegenerative disorders or movement disorders selected from Parkinson's disease or progressive supernuclear palsy, Huntington's disease, multiple system atrophy, corticobasal degeneration, Wilson's disease, Hallerrorden-Spatz disease, progressive pallidal atrophy, Dopa-responsive dystonia-Parkinsonism, spasticity, Alzheimer's disease or other disorders of the basal ganglia which result in dyskinesias.
